Merck KGaA Weighed by Drug Trial Setback
Wall Street Journal
Shares in Germany’s Merck fell after it said the FDA had placed a partial clinical hold on the initiation of new patients in the Phase 3 study of evobrutinib, the drugmaker’s treatment for multiple sclerosis.